TransMedics Group, Inc.’s $104.7 Million Initial Public Offering

Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc., which included 853,500 shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares.

TransMedics Group, Inc. is listed on the Nasdaq Global Market under the symbol “TMDX.”

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Canaccord Genuity LLC acted as underwriters in the deal.

TransMedics Group, Inc. is a commercial-stage medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. (Picture) and associates Jennifer Ying Lan and Jacqueline Marino. Partner David R. Bauer and associates Jesse L. Hallock and Yifu Chen provided intellectual property and technology advice. The tax team included partner Rachel D. Kleinberg and associate Danielle Rapaccioli. Associate Abigail Lane provided executive compensation advice. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Yifu Chen – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Jesse Hallock – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Abigail Lane – Davis Polk & Wardwell; Jacqueline Marino – Davis Polk & Wardwell; Danielle Rapaccioli – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell; Jennifer Ying Lan – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Canaccord Genuity; Cowen and Company; J.P. Morgan Securities LLC; Morgan Stanley;


Author: Ambrogio Visconti